Quick Answer
KalVista Pharmaceuticals, Inc. reported Research And Development Expense of $71.71 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -16.8% in Research And Development Expense from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $1.43 million | Q2 2014: $1.75 million | Q3 2014: $2.09 million | Q1 2015: $3.90 million | Q2 2015: $4.50 million | Q3 2015: $3.53 million | Q1 2016: $3.62 million | Q1 2016: $3.53 million | Q2 2016: $947.0 thousand | Q3 2016: $3.40 million | Q3 2016: $332.0 thousand | Q4 2016: $2.93 million | Q1 2017: $3.34 million | Q3 2017: $3.48 million | Q4 2017: $4.36 million | Q1 2018: $4.55 million | Q3 2018: $8.36 million | Q4 2018: $7.88 million | Q1 2019: $7.65 million | Q3 2019: $9.69 million | Q4 2019: $9.79 million | Q1 2020: $11.23 million | Q3 2020: $11.17 million | Q4 2020: $9.15 million | Q1 2021: $9.10 million | Q3 2021: $13.67 million | Q4 2021: $17.55 million | Q1 2022: $19.74 million | Q3 2022: $18.19 million | Q4 2022: $18.08 million | Q1 2023: $20.06 million | Q3 2023: $19.31 million | Q4 2023: $19.09 million | Q1 2024: $22.52 million | Q3 2024: $26.61 million | Q3 2024: $18.68 million | Q4 2024: $16.61 million | Q1 2025: $12.59 million | Q3 2025: $15.16 million | Q3 2025: $11.99 million.
- Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Research And Development Expense has grown by 1,595.6%.
- Historical annual values: Fiscal year 2025: $71.71 million | Fiscal year 2024: $86.17 million | Fiscal year 2023: $80.28 million | Fiscal year 2022: $70.17 million | Fiscal year 2021: $41.29 million | Fiscal year 2020: $40.19 million | Fiscal year 2019: $35.02 million | Fiscal year 2018: $18.24 million | Fiscal year 2017: $12.67 million | Fiscal year 2016: $14.66 million | Fiscal year 2015: $16.20 million | Fiscal year 2015: $8.29 million | Fiscal year 2014: $8.29 million | Fiscal year 2013: $4.23 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: